However, further investigations are warranted to reveal biomarkers that can more conveniently and cost-effectively detect responders to osimertinib among NSCLC patients with EGFR-T790M mutations because 6% of them showed the disease progression treated with osimertinib in a clinical trial [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.